ライフサイエンスコーパス: asthenia

1 >= 2 TEAEs of nausea, vomiting, fatigue, and asthenia.

2 s of this docetaxel schedule are fatigue and asthenia.

3 effort, and was associated with anorexia and asthenia.

4 ed dose adjustment due to low bicarbonate or asthenia.

5 o known as hereditary equine regional dermal asthenia.

6 common toxicities included rash, nausea, and asthenia.

7 oot syndrome, diarrhea, nausea/vomiting, and asthenia.

8 in the understanding of cancer cachexia and asthenia.

9 d therapy to manage both cancer cachexia and asthenia.

10 a, vomiting, pneumonia, dyspnea, anemia, and asthenia.

11 ouracil and leucovorin group) and fatigue or asthenia (11 [13%] vs three [3%]).

12 events in more than 10% of all patients were asthenia (11 [18%] of 60 in the 12-week group; 19 [32%]

13 peripheral sensory neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (

14 acebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm prog

15 ere facial oedema (16 [64%] of 25 patients), asthenia (14 [56%]), and pruritus (14 [56%]).

16 thrombocytopenia (7% and 11%, respectively), asthenia (14% and 16%, respectively), and neurotoxicity

17 geusia (269 [54%]), weight loss (162 [33%]), asthenia (141 [28%]), decreased appetite (126 [25%]), ag

18 ment-emergent adverse events were fatigue or asthenia (15 [12%] of 124 patients), hot flush (six [5%]

19 tening toxicity was experienced by 34%, with asthenia (15%) and neuropsychiatric difficulties (7%) be

20 The most common adverse events were asthenia (16 [39%] patients), headache (11 [27%] patient

21 Main adverse effects were asthenia (16 [46%]) and neuropathy (14 [40%]).

22 vs 49 [16%]), fatigue (23 [7%] vs 18 [6%]), asthenia (16 [5%] vs 8 [3%]), bone pain (16 [5%] vs 5 [2

23 [14%] of 189 patients), diarrhoea (17 [9%]), asthenia (16 [8%]), weight decrease (16 [8%]), and PPE (

24 (AEs) included neutropenia (25.4% v 20.3%), asthenia (16.9% v 13.8%), and anemia (17.3% v 12.2%) in

25 up were anorexia (31 [13%] of 240 patients), asthenia (20 [8%]), coughing (16 [7%]), abnormal behavio

26 ncluded neutropenic fever (24% of patients), asthenia (22%), infection (13%), stomatitis (9%), neuros

27 r 4 adverse events were neutropenia (39.0%), asthenia (22.0%), abdominal pain (22.0%), and thrombocyt

28 dverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%

29 r severe (grades 3 and 4) toxic effects were asthenia (25%), nausea (11%), fever (8%), vomiting (8%),

30 five [1%]), dyspnoea (22 [4%] vs nine [2%]), asthenia (27 [5%] vs 17 [3%]), and pulmonary embolism (3

31 cutoff were diarrhoea (45 [26%] of 171) and asthenia (28 [16%]); the most common grades 3-4 treatmen

32 ocytopenia (85.1%), neutropenia (63.8%), and asthenia (29.8%) in the escalation phase, and thrombocyt

33 hypertriglyceridemia (84%), dry skin (34%), asthenia (30%), and headache (27%).

34 ted adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and

35 dache (58 patients, 23% [95% CI 18-29]), and asthenia (35 patients, 14% [95% CI 10-19]).

36 bo group), fatigue (62 [8%] vs 42 [6%]), and asthenia (40 [5%] vs 23 [3%]); grade 3-4 pleural effusio

37 rade 1/2 adverse events were diarrhea (55%), asthenia (44%), and acne-like follicular rash (46%).

38 5%), anemia (8%), thrombocytopenia (7%), and asthenia (5%).

39 e maculopapular rash (76%), mucositis (70%), asthenia (50%), and nausea (43%).

40 hermal dysregulation (83.6%), cough (58.9%), asthenia (52.7%), polypnea (39.9%), and gastrointestinal

41 rse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), co

42 f 98 patients), abnormal behaviour (6 [6%]), asthenia (6 [6%]), and pruritus (5 [5%]).

43 ents at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each).

44 Patients presented fever (74.7%), asthenia (67.7%), emesis (38.2%), diarrhea (28.3%), and

45 tomatitis (12.6%/1.8%), mucositis (9.0%/0%), asthenia (7.2%/0%), and hypertension (4.5%/0%).

46 (27 [66%] of 41]), diarrhoea (19 [46%]), and asthenia (8 [20%]).

47 elated grade 3/4 AEs were fatigue (9% v 1%), asthenia (8% v 2%), and hand-foot syndrome (7% v 0%).

48 uding headache, new injection site reaction, asthenia, abdominal pain, Crohn's disease-related anemia

49 had thrombocytopenia, 10.1% versus 2.9% had asthenia and 12.3% versus 0.0% had neuropathy.

50 Weight loss, asthenia and anorexia were also highly characteristic, b

51 y of lower limb pain associated with unusual asthenia and diffuse arthralgia over the past 3 weeks.

52 Grade III to IV asthenia and fatigue were observed in 6% of patients.

53 The most frequent adverse events were asthenia and headache, pruritus, and fatigue.

54 enocarcinoma (in three [7%] of 41 patients); asthenia and myocardial infarction in patients with non-

55 dies, we also observed a higher incidence of asthenia and serious vascular thrombotic events than exp

56 an acne-like rash (88.6%), dry skin (34.3%), asthenia and skin disorders (31.4%), mucositis/stomatiti

57 tients, diarrhoea in two (10%) patients, and asthenia and vomiting in one (5%) patient each.

58 reported adverse experiences were headache, asthenia, and constipation.

59 he most common adverse events were headache, asthenia, and gastrointestinal symptoms.

60 ommon adverse events were fatigue, insomnia, asthenia, and headache.

61 nts (AEs); the most common were neutropenia, asthenia, and hypothyroidism.

62 patients with grade 3 or 4 thrombocytopenia, asthenia, and liver toxicity was significantly higher in

63 ndition that causes widespread chronic pain, asthenia, and muscle stiffness, as well as in some cases

64 adverse events, such as rhinitis, headache, asthenia, and peripheral edema, were reversible on drug

65 nal (diarrhea, nausea, stomatitis) toxicity, asthenia, and rash.

66 common toxicities included diarrhea, nausea, asthenia, and rash.

67 cycle included leukopenia, hypophosphatemia, asthenia, anemia, and hypertriglyceridemia for all patie

68 Common adverse events were asthenia, anorexia, pain, and somnolence.

69 Fatigue and asthenia are the DLTs; other nonhematologic toxicities,

70 curred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevatio

71 r not) in the anamorelin group were fatigue, asthenia, atrial fibrillation, and dyspnoea (two [5%] ea

72 , anemia, peripheral neuropathy, and fatigue/asthenia being the most common grade >=3 adverse events.

73 itial infusion were mainly grade I/II fever, asthenia, chills, nausea, rash, and urticaria.

74 Cachexia and asthenia commonly coexist, but they can occur independen

75 rated and were associated with dose-limiting asthenia, diarrhea, and AST/ALT elevation.

76 y than nonpregnant women to report anorexia, asthenia, diarrhea, fever, myalgias/arthralgias, nausea,

77 ea (seven [35%] patients), and diarrhoea and asthenia (each six [30%] patients).

78 9 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [2%]), and neutropenia (ten

79 ommon of which were fatigue (four [2%]), and asthenia, elevated lipase, hypophosphataemia, and pneumo

80 The dose-limiting toxicity was asthenia, establishing the maximum tolerated dose of 27

81 of grade 3/4 neutropenia, thrombocytopenia, asthenia, fatigue, diarrhea, and hand-foot syndrome.

82 grade; 18% with grade 3), and a composite of asthenia, fatigue, malaise, or lethargy (56% with any gr

83 Therapy was generally well tolerated, but asthenia, fatigue, vertigo, dizziness, sense of imbalanc

84 er, including rash/dermatitis, diarrhea, and asthenia/fatigue were more frequent in the sunitinib plu

85 Vomiting, nausea, asthenia/fatigue, and anorexia were common but not sever

86 red by a number of adverse effects including asthenia/fatigue.

87 completed weekly questionnaires quantifying asthenia/fatigue.

88 ties included nausea and vomiting, alopecia, asthenia, fever, and anemia.

89 of 96 patients), diarrhoea (five [5%]), and asthenia (five [5%]).

90 e most common nonhematologic toxicities were asthenia, flu-like symptoms, and fluid retention.

91 lacebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one [2%]).

92 five [12%] of 42 in the placebo group), and asthenia (four [9%] of 44 patients in the selumetinib gr

93 k concepts of nosos (biological disease) and asthenia (functional decline) to frame the shift in Alzh

94 The most common adverse events were asthenia, headache, and fatigue.

95 y or probably related to study drug included asthenia, headache, and nausea.

96 Hereditary equine regional dermal asthenia (HERDA), a degenerative skin disease that affec

97 orses with hereditary equine regional dermal asthenia (HERDA), an equine model of Ehlers-Danlos syndr

98 en patients had dose-limiting but reversible asthenia, hyperbilirubinemia, and azotemia or acidosis;

99 aneous squamous-cell carcinoma in ten (12%), asthenia in four (5%), and basal-cell carcinoma in four

100 e patients), diarrhea (in 59.4%), fatigue or asthenia (in 59.0%), decreased appetite (in 50.2%), decr

101 Adverse events included headaches, asthenia, infections, and hypersensitivity.

102 openia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransfe

103 A 14-year-old boy presented with asthenia, low back pain, and abdominal distention.

104 and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea.

105 influenza had more general symptoms (fever, asthenia, myalgia).

106 mmon of which were pruritus (n = 15; 14.3%), asthenia (n = 14; 13.3%), and fatigue (n = 13; 12.4%).

107 events overall were headache (n = 22 [19%]), asthenia (n = 16 [14%]), and fatigue (n = 11 [10%]).

108 enias (n = 10), nausea/vomiting (n = 9), and asthenia (n = 5).

109 ib group included hypertension (n=62 [14%]), asthenia (n=35 [8%]), and hand-foot syndrome (n=29 [6%])

110 mar-plantar erythrodysesthesia [PPE], n = 3; asthenia, n = 2; cardiac, n = 2; neutropenia, n = 1; sto

111 s (of any grade) included fatigue, diarrhea, asthenia, nausea, and dizziness.

112 se related: injection site reactions, cough, asthenia, nausea, anorexia, weight loss, and increased s

113 vent occurring in 5% patients) were fatigue, asthenia, nausea, dyspnoea, hypertension, and headache;

114 Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significantly more patients in grou

115 The most common toxicities were asthenia, occurring in 83% of patients (grade 3 or 4 in

116 patients), thrombocytopenia (one [4%]), and asthenia (one [4%]).

117 sorders (three [13%] at 200 mg twice a day), asthenia (one [7%] at 300 mg twice a day), infections an

118 st common adverse events in both groups were asthenia or fatigue (270 [54%] of 503 patients on eribul

119 3%, respectively), diarrhea (34.6% v 41.0%), asthenia or fatigue (43.5% v 38.1%), and neutropenia (gr

120 150 [40%]), diarrhoea (97 [26%] vs 30 [8%]), asthenia or fatigue (91 [24%] vs 45 [12%]), and peripher

121 ents 80 years exhibited falls (P = .002) and asthenia (P = .002).

122 ual loss, decreased coordination, widespread asthenia, paraplegia, quadriplegia, and sensory impairme

123 Drug-related adverse events such as asthenia, poor appetite, dizziness, nausea, and vomiting

124 Common adverse events included headache, asthenia, pruritus, and diarrhea.

125 y; most common toxicities included diarrhea, asthenia, rash, nausea, and vomiting.

126 le patients and were characterized by cough, asthenia, sensory neuropathy, anorexia, serum sickness,

127 and eight [6%] of 134 in the control group), asthenia (six [2%] and four [3%]), and thrombocytopenia

128 atients given LY334370 than placebo reported asthenia, somnolence, and dizziness.

129 ng the GRBAS (grade, roughness, breathiness, asthenia, strain) scale.

130 Many other factors contribute to asthenia, such as anaemia, autonomic failure, and muscul

131 %] of 135 patients in the placebo group) and asthenia (ten [7%] vs six [4%]).

132 ncreased lipase (22 [6%] vs three [1%]), and asthenia (tjree [1%] vs eight [2%]).

133 commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxic

134 Grade 3 asthenia was dose limiting at the highest dose level tes

135 re common in the temsirolimus group, whereas asthenia was more common in the interferon group.

136 g and 60 mg, respectively; transient grade 3 asthenia was observed on schedule A at 80 mg (one patien

137 tions, upper abdominal pain, arthralgia, and asthenia were more common in the 2-mg and 10-mg groups c

138 Grade III fatigue and asthenia were observed in all three patients treated at